CRSP (CRISPR Therapeutics AG Common Shares) stock: $56.56, $5.47B market cap, $2.36B cash, $3.69B EV, $5.97B fully diluted market cap. Next expected readout: Jun-27. Lead program: CTX340 (Hypertension), Phase 2. Data from Fully Diluted's biotech stocks database.
Enterprise value
$3,690.7M
Balance sheet
| Cash | $2,364.4M |
|---|
| Debt | $586.2M |
|---|
| Net cash | $1,778.2M |
|---|
| Enterprise value | $3,690.7M |
|---|
| Basic shares | 96.7M shares |
|---|
| Fully diluted shares | 105.6M shares |
|---|
| Fully diluted market cap | $5,973.4M |
|---|
| Cash per share | $24.45 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading CRSP daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Jul 13 - Aug 24 | CTX310 | Phase 1 | Cardiovascular; Metabolic Disease; Dyslipidemias | — |
| Jul 18 - Aug 29 | CTX001 | Phase 3 | Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance | — |
| Dec 26, 2027 - Feb 6, 2028 | CTX001 | Phase 3 | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn | — |
| Aug 12 - Sep 23 | CTX340 | Phase 2 | Hypertension | — |
| Feb 10 - Mar 24 | CTX112 | Phase 2 | Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | — |
| Feb 12 - Mar 26 | CTX112 | Phase 2 | B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy | — |
| Feb 11 - Mar 24 | CTX112 | Phase 1 | SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis | — |
| Jan 12 - Feb 23 | CTX112 | Phase 2 | Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia | — |
| Nov 11 - Dec 23 | CTX001 | Phase 3 | Beta-Thalassemia; Thalassemia; Sickle Cell Disease | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
CASGEVY
Approved · Active Modality: ex vivo CRISPR/Cas9-edited autologous cell therapy
Aliases exagamglogene autotemcel, exa-cel
Target BCL11A
Partnerships Vertex Pharmaceuticals: joint development and commercialization; Vertex leads and has all decision-making; net profits/losses split 40% CRISPR / 60% Vertex; PRV proceeds sharing ($43M or 42% of net proceeds)
Indications- Sickle cell disease (Approved)
- Transfusion-dependent beta thalassemia (Approved)
Status note Approved product; Vertex is the manufacturer and exclusive license holder. Phase 3 pediatric studies CLIMB-151 (SCD ages 5-11) and CLIMB-141 (TDT ages 5-11) ongoing with positive ASH December 2025 data.
Zugocabtagene geleucel
Phase 1 · Active Modality: allogeneic CAR T cell therapy (CRISPR-edited)
Aliases zugo-cel, CTX112
Target CD19
Partnerships Eli Lilly: collaboration and clinical supply agreement to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas
Indications- Relapsed/refractory B-cell malignancies (Phase 1)
- Autoimmune diseases (SLE, systemic sclerosis, inflammatory myositis, ITP, warm AIHA) (Phase 1)
Status note Next-generation gene-edited healthy-donor allogeneic CAR T targeting CD19; edits designed to enhance potency, reduce exhaustion, evade immunity. RMAT designation for relapsed/refractory follicular lymphoma and marginal zone lymphoma.
CTX310
Phase 1 · Active Modality: in vivo CRISPR/Cas9 gene editing (LNP-delivered Cas9 mRNA + gRNA)
Target ANGPTL3
Indications- Heterozygous/homozygous familial hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia (Phase 1)
Status note Most advanced in vivo program; Phase 1b prioritizes severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data presented November 2025.
CTX611
Phase 2 · Active Modality: siRNA (long-acting, subcutaneous)
Aliases SRSD107
Target F11 (Factor XI)
Partnerships Sirius Therapeutics: collaboration, option and license agreement (May 2025); 50/50 development cost and profit share; CRISPR leads Phase 3/US commercialization; up to $87.5M milestones
Indications- Thromboembolic disease (VTE prevention in total knee arthroplasty) (Phase 2)
Status note Targets coagulation factor XI mRNA; semi-annual subcutaneous dosing potential. Two Phase 1 trials completed by Sirius.
CTX213
Preclinical · Active Modality: cell therapy (unencapsulated iPSC-derived precursor islet cells, deviceless)
Indications- Type 1 diabetes (Stage not disclosed)
Status note Regenerative medicine program; preclinical efficacy via direct administration. Separate non-exclusive IP license to Vertex for hypoimmune T1D cell therapies (milestones + royalties).
CTX340
Preclinical · Active Modality: in vivo CRISPR/Cas9 gene editing
Target AGT (angiotensinogen)
Indications- Refractory hypertension (Stage not disclosed)
Status note IND-enabling studies ongoing.
CTX460
Preclinical · Active Modality: in vivo gene editing (SyNTase platform)
Target SERPINA1
Indications- Alpha-1 antitrypsin deficiency (Stage not disclosed)
Status note First candidate from proprietary SyNTase editing platform.
CTX321
Preclinical · Active Modality: in vivo CRISPR/Cas9 gene editing
Target LPA
Indications- Elevated lipoprotein(a) (Stage not disclosed)
Status note Next-generation LPA program with updated guide RNA (~2x potency vs CTX320 in preclinical testing); IND-enabling studies ongoing.
Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.